



NCI SBIR AND YOUR CITY:

WASHINGTON D.C.



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$12.6 million** in funding across **14 Phase II SBIR/STTR grants** to small businesses in Washington D.C. The following economic impact estimates quantify the program's contributions to the city's economy:



\$20.2M

IN TOTAL DIRECT SALES



\$85.3M

IN TOTAL ECONOMIC IMPACT



400

JOBS CREATED



\$2.6M

IN STATE & LOCAL TAXES COLLECTED



9

COMPANIES WITH SALES

**These city-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Washington D.C.: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$20.6M in funding across all grants to oncology-focused small businesses in the city.*

Success story:

ONCOVIR, INC.

Oncovir used SBIR funds to evaluate the intratumoral administration of Hiltonol® (poly-ICLC), a novel immunomodulator that when combined with an antigen, generates a weighted immune response for fighting tumors and viral infections. Hiltonol® has been used in multiple phase I and phase II clinical trials to strengthen the immune system's ability to see and respond to cancer cells for various cancer types.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.